MAGE-A3 + GM-CSF + poly-ICLC

This is a combination immunotherapy regimen consisting of a cancer-testis antigen vaccine targeting MAGE-A3, the immune adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), and the toll-like receptor 3 agonist Poly-ICLC (Hiltonol). The approach is designed to enhance anti-tumor immune responses in patients with multiple myeloma following autologous stem cell transplantation. MAGE-A3 is a tumor-associated antigen expressed in various cancers but not in normal tissues except for testis. The vaccine component consists of synthetic peptides derived from MAGE-A3 to stimulate T-cell responses against tumor cells expressing this antigen. GM-CSF acts as an immunostimulant to recruit and activate dendritic cells at the vaccination site, enhancing antigen presentation. Poly-ICLC is a synthetic double-stranded RNA that functions as an agonist for toll-like receptor 3 (TLR3), further boosting innate and adaptive immune activation by mimicking viral infection signals. The combination aims to prime and boost both cellular and humoral immunity against myeloma cells post-transplantation[1][2][6]. Clinical trials have demonstrated that this regimen can induce robust vaccine-specific T-cell responses with acceptable safety profiles.

Brand names

Leukine

Other names

MAGE-A3 peptide vaccine + granulocyte-macrophage colony-stimulating factor + Poly-ICLCMAGE-A3/GM-CSF/Poly-ICLC combination